An update on gene therapy for the treatment of lipoprotein lipase deficiency

References

• Wang H, Astarita G, Taussig MD, et al. Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity. Cell Metab. 2011;13(1):105–113.
   PubMed Web of Science ®Google Scholar
• Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297(2):E271–E288.
   PubMed Web of Science ®Google Scholar
• Wang H, Eckel RH. What are lipoproteins doing in the brain? Trends Endocrinol Metab. Epub November 2, 2013.
   Google Scholar
• Wang H, Eckel RH. Lipoprotein lipase in the brain and nervous system. Annu Rev Nutr. 2012;32:147–160.
   Web of Science ®Google Scholar
• Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 2002;43(12):1997–2006.
   PubMed Web of Science ®Google Scholar
• Gotoda T, Yamada N, Kawamura M, et al. Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. J Clin Invest. 1991;88(6):1856–1864.
   Web of Science ®Google Scholar
• Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet. 2008;371(9607):143–152.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Ross CJ, Hayden MR. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Hum Gene Ther. 2013;24(5):472–478.
   PubMed Web of Science ®Google Scholar
• Burnett JR, Hooper AJ. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther. 2009;11(6):681–691.
   Google Scholar
• Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361–369.
   PubMed Web of Science ®Google Scholar
• Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010;11(1):55–60.
   PubMed Web of Science ®Google Scholar
• Bruno M. Gene therapy coming of age – prevention of acute pancreatitis in lipoprotein lipase deficiency through alipogene tiparvovec. Eur Gastroenterol Hepatol Rev. 2010;6(1):48–53.
   Google Scholar
• Bryant LM, Christopher DM, Giles AR, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. 2013;24(2):55–64.
   PubMed Web of Science ®Google Scholar
• Excoffon KJ, Liu G, Miao L, et al. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol. 1997;17(11):2532–2539.
   Web of Science ®Google Scholar
• Liu G, Ashbourne Excoffon KJ, Wilson JE, et al. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Hum Gene Ther. 2000;11(1):21–32.
   Web of Science ®Google Scholar
• Ross CJ, Liu G, Kuivenhoven JA, et al. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol. 2005;25(10):2143–2150.
   PubMed Web of Science ®Google Scholar
• Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol. 2006;26(6):1236–1245.
   Web of Science ®Google Scholar
• Ross CJ, Twisk J, Meulenberg JM, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum Gene Ther. 2004;15(9):906–919.
   PubMed Web of Science ®Google Scholar
• Schlaepfer IR, Eckel RH. Plasma triglyceride reduction in mice after direct injections of muscle-specific lipoprotein lipase DNA. Diabetes. 1999;48(1):223–227.
   Web of Science ®Google Scholar
• Rip J, Nierman MC, Sierts JA, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther. 2005;16(11):1276–1286.
   PubMed Web of Science ®Google Scholar
• Ross CJ, Twisk J, Bakker AC, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther. 2006;17(5):487–499.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009;114(10):2077–2086.
   PubMed Web of Science ®Google Scholar
• Carpentier AC, Frisch F, Labbé SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635–1644.
   PubMed Web of Science ®Google Scholar
• Gan SI, Edwards AL, Symonds CJ, Beck PL. Hypertriglyceridemia-induced pancreatitis: A case-based review. World J Gastroenterol. 2006;12(44):7197–7202.
   Web of Science ®Google Scholar
• European Medicines Agency. Assessment Report: Glybera. London: European Medicines Agency; 2012.
   Google Scholar
• Ylä-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012;20(10):1831–1832.
   PubMed Web of Science ®Google Scholar
• Melchiorri D, Pani L, Gasparini P, et al. Regulatory evaluation of Glybera in Europe – two committees, one mission. Nat Rev Drug Discov. 2013;12(9):719.
   PubMed Web of Science ®Google Scholar
• Britten CM, Walter S, Janetzki S. Immunological monitoring to rationally guide AAV gene therapy. Front Immunol. 2013;4:273.
   Web of Science ®Google Scholar
• Whalen J. Gene-therapy approval marks major milestone. Wall Street Journal. November 2, 2012.
   Google Scholar